Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the first quarter ended March 31, 2009.

"We have now concluded three Phase I trials of ANA598, including a study in HCV patients that demonstrated potent antiviral activity over three days," said Steve Worland, Ph.D., Anadys' President and CEO. "Coupled with very favorable results at three months in our chronic toxicology studies and ongoing manufacturing activities, the conclusion of these Phase I clinical studies positions the program to be ready in mid-2009 for the first Phase II study of ANA598 in combination with pegylated interferon and ribavirin, a study with the potential to demonstrate the impact of ANA598 on durable clinical benefit, known as SVR, in HCV patients."

Financial Results

As of March 31, 2009, the Company's cash, cash equivalents and securities available-for-sale totaled $20.8 million compared to $27.9 million as of December 31, 2008.

Research and development expenses were $6.9 million for the first quarter of 2009 compared to $6.0 million for the first quarter of 2008. The $0.9 million increase primarily resulted from a $1.7 million increase in development costs for ANA598 in the first quarter of 2009 compared to the first quarter of 2008, partially offset by a decrease in our ANA773 development costs. The ANA598 development costs were associated with our completed Phase Ib clinical trial which was initiated during September 2008, our 14-day healthy volunteer study which was initiated in February 2009 and our on-going long-term chronic toxicology studies which were initiated during Septe
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... 2014   Synthetic Biologics, Inc. (NYSE MKT: ... serious infections and diseases, announced today that the U.S. ... Allowance for a composition of matter patent application that ... program, SYN-004. This is Synthetic Biologics, first allowed patent ... adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... WA, May 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. ... filed an investigational new,drug (IND) application with ... a small molecule phosphatidylinositol-3-kinase (PI-3-kinase),inhibitor for the ... plans to initiate a Phase 1 clinical ...
... produced tiny liquid crystal devices with electrodes made from ... computer and TV displays based on this technology. , ... Dr Kostya Novoselov and colleagues from The School of ... report on the use of graphene as a transparent ...
... SAN DIEGO, April 30 Anadys Pharmaceuticals,Inc. (Nasdaq: ... improving,patient care by developing novel medicines in the ... financial results and highlights for the first,quarter ended ... in both of our development programs,during the first ...
Cached Biology Technology:Oncothyreon files investigational new drug application for PX-866 oncology compound 2Oncothyreon files investigational new drug application for PX-866 oncology compound 3Graphene-based gadgets may be just years away 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 8
(Date:10/17/2014)... is available in German . ... very few drugs. When treating overdoses, doctors are often limited ... difficult if there is a combination of drugs involved. So ... accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from ... find an answer to this question. "The task was to ...
(Date:10/16/2014)... are anything but sustainable: environmental damage to soil ... increasingly evident. Despite their disadvantages, however, monocultures remain ... the sole possibility of achieving higher yields in ... an ecology professor at the University of Zurich, ... forestry. After all, a new study carried out ...
(Date:10/15/2014)... assess the pandemic risk from strains of influenza virus ... allow ourselves to become complacent that the most substantial ... scientists. , Influenza pandemics arise when a new virus ... widespread immunity – spreads in the human population. There ... years, the worst of which – the 1918 Spanish ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... Researchers at the Hebrew University of Jerusalem have discovered ... utilizing human embryonic stem cells. Their work paves the ... stem cell therapy. Human embryonic stem cells ... the mature human body (and are hence defined as ...
... people are alike." Yet when we consider the thousands of ... it is remarkable how much alike we are. ... but a general property of life. Biologists have long pondered ... great variation in genetics as well as environmental conditions. ...
... for Research Resources (NCRR), part of the National ... up to an estimated $122 million over the ... (IDeA) Networks of Biomedical Research Excellence (INBRE) in ... and sharing of research resources and expertise, these ...
Cached Biology News:Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy 2Researchers find snippet of RNA that helps make individuals remarkably alike 2NIH grants $122 million in Institutional Development Awards 2NIH grants $122 million in Institutional Development Awards 3
... The powerful solution for all plate washing ... format. ,The PW 384 provides an ... field of Drug Discovery (Assay development, Screening or ... speed ,The PW 384 has set ...
... Model 1575 immunowash microplate washer, 100-240 V, ... have flat-, U-, or V-bottom wells. This ... needle positions to an accuracy of 0.1 ... overflow washing. It can store up to ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Biology Products: